Treatment with TcdBFBD, but not TcdBmu, reduced the viability of organoids formed from the p53/BRCA1-deficient or C3(1)-Tag tumor cells; in contrast, TcdBFBD treatment did not affect organoids formed from MMTV-PyMT luminal tumor organoids (Fig 3A). Here, TP53 is linked to neoplasm.